Although based on a single study with two independent cohorts, sEV‐TDP‐43 demonstrated a notably high SMD compared to NHC (1.53 [0.87–2.19]) and progressive supranuclear palsy (1.62 [1.25–1.99]), warranting further validation. Here, TARDBP is linked to progressive supranuclear palsy.